First glyphosate-cancer trial appeal could give Bayer ‘significant leverage’ in settlement talks with over 50,000 plaintiffs


A California appeals court on [June 2] will hear oral arguments in agrochemical giant Monsanto’s bid to toss a $78.5 million award stemming from the first trial over the company’s popular “Roundup” weed killer ….

Monsanto, which was acquired by Bayer in 2018, will ask a three-judge panel to enter judgment in their favor or to order a new trial. The court’s decision will have a major impact on ongoing settlement discussions involving over 50,000 plaintiffs who claim they developed cancer from exposure to the chemical glyphosate in herbicides like Roundup.

The $289 million verdict in that trial (subsequently reduced to $78.5 million) and other verdicts that followed battered Bayer’s stock price, and whether or not the verdict survives the appeal will give significant leverage to plaintiffs or Bayer depending on the outcome.

Related article:  Can the evolution of elephants show us how to treat, prevent cancer?

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend